Actively Recruiting
Phase IBII Study of SHR-1826 Injection with Other Cancer Treatments for Adults 18 to 75 with Non-small Cell Lung Cancer
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-04-17
400
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of SHR-1826, an injectable drug, along with other anti-cancer treatments in adults with non-small cell lung cancer NSCLC. This is an open-label, multi-center, Phase IBII clinical trial aimed at finding the recommended dose for Phase II and assessing how well the treatment works in this patient group. Participants will receive SHR-1826 injections combined with other antitumor therapies, including drugs like SHR-1316, SHR-9839, SHR-8068, Ametinib mesylate, BP-102, and Carboplatin. The study observes multiple doses over an average of one year, with treatment monitoring for safety and response. During the trial, participants will undergo evaluations including tumor tissue collection, imaging to measure lesions, and blood tests to monitor drug levels and immune response. Researchers will track adverse events, tumor response rates, disease control, progression-free survival, and overall survival for about one year. Safety and drug concentration will also be closely followed throughout the study period.
CONDITIONS
Brief Title
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Research Team
Y
Yijun Jia
T
Tingting Lei
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
